http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE47413-E
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c915886666f6f9cd791df489c0dbae9f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4965 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0021 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0052 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4965 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 |
| filingDate | 2017-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb5c77836cb1d60754451d0ef89b27ec http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68f4fe0d44b1f8a2192d33a003ea45e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd3ea4b127911f601f845789c8f91234 |
| publicationDate | 2019-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-RE47413-E |
| titleOfInvention | Pyrazine derivatives and uses thereof in renal monitoring |
| abstract | The present invention relates to pyrazine derivatives such as those represented by Formulas I and II below. n nX 1 to X 4 of the compounds of Formulas I and II may be characterized as electron withdrawing groups. In contrast, Y 1 to Y 4 of the compounds of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing renal function. In particular, an effective amount of a pyrazine derivative of the invention may be administered into a body of a patient. The pyrazine derivative that is in the body may be exposed to visible and/or infrared light to cause spectral energy to emanate from the pyrazine derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient. |
| priorityDate | 2004-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 273.